We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Amazon.com, Stryker, Lam Research and ImmuCell
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 4, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Stryker Corp. (SYK - Free Report) , Lam Research Corp. (LRCX - Free Report) and ImmuCell Corp. (ICCC - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Amazon, Stryker and Lam Research
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Stryker Corp. and Lam Research Corp., as well as a micro-cap stock, ImmuCell Corp. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
Amazon’s shares have outperformed the Zacks Internet – Commerce industry over the past year (+45.5% vs. +40.8%). The Zacks analyst believes that strengthening AWS services portfolio and its growing adoption rate have contributed well to the stock's performance. Ultrafast delivery services, expanding content portfolio and Amazon’s expanding global presence have also benefited the company. Deepening focus on generative AI is a major plus.
However, macroeconomic challenges remain headwinds. Rising transportation and fulfillment center costs are concerns.
Stryker’s shares have outperformed the Zacks Medical - Products industry over the past year (+33.9% vs. +20.9%). The Zacks analyst believes that strong international sales, ongoing procedural recovery and a strong order book for capital equipment bode well for the company. Strong customer demand is a major plus.
Yet, inflationary pressure and supply-chain challenges continue to plague Stryker. Stiff competition in the MedTech space remains a headwind.
Shares of Lam Research have underperformed the Zacks Electronics – Semiconductors industry over the past year (+10.6% vs. +45.7%). Per the Zacks analyst, global spending on mature nodes is likely to be flat year over year. Growing tensions between the United States and China remain major concerns and have contributed to the stocks underperformance this year.
However, the company is riding on its strength across 3D DRAM and advanced packaging technologies. Also, rebound in the system business owing to improving memory spending is a positive.
Immucell’s shares have underperformed the Zacks Medical - Products industry over the last six months (-3.9% vs. +11.9%). The Zacks analyst believes that the company has been hindered by high production costs and increased depreciation from expanded facilities. High customer concentration, shareholder dilution and competition from giants like Zoetis and Merck also pose risks.
Yet, robust customer demand for First Defense has been a key driver of sales growth. The remediation of contamination issues and investments in capacity expansion have positioned the company to stabilize output at higher levels.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Amazon.com, Stryker, Lam Research and ImmuCell
For Immediate Release
Chicago, IL – December 4, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Stryker Corp. (SYK - Free Report) , Lam Research Corp. (LRCX - Free Report) and ImmuCell Corp. (ICCC - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Amazon, Stryker and Lam Research
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Stryker Corp. and Lam Research Corp., as well as a micro-cap stock, ImmuCell Corp. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Amazon’s shares have outperformed the Zacks Internet – Commerce industry over the past year (+45.5% vs. +40.8%). The Zacks analyst believes that strengthening AWS services portfolio and its growing adoption rate have contributed well to the stock's performance. Ultrafast delivery services, expanding content portfolio and Amazon’s expanding global presence have also benefited the company. Deepening focus on generative AI is a major plus.
However, macroeconomic challenges remain headwinds. Rising transportation and fulfillment center costs are concerns.
(You can read the full research report on Amazon here >>>)
Stryker’s shares have outperformed the Zacks Medical - Products industry over the past year (+33.9% vs. +20.9%). The Zacks analyst believes that strong international sales, ongoing procedural recovery and a strong order book for capital equipment bode well for the company. Strong customer demand is a major plus.
Yet, inflationary pressure and supply-chain challenges continue to plague Stryker. Stiff competition in the MedTech space remains a headwind.
(You can read the full research report on Stryker here >>>)
Shares of Lam Research have underperformed the Zacks Electronics – Semiconductors industry over the past year (+10.6% vs. +45.7%). Per the Zacks analyst, global spending on mature nodes is likely to be flat year over year. Growing tensions between the United States and China remain major concerns and have contributed to the stocks underperformance this year.
However, the company is riding on its strength across 3D DRAM and advanced packaging technologies. Also, rebound in the system business owing to improving memory spending is a positive.
(You can read the full research report on Lam Research here >>>)
Immucell’s shares have underperformed the Zacks Medical - Products industry over the last six months (-3.9% vs. +11.9%). The Zacks analyst believes that the company has been hindered by high production costs and increased depreciation from expanded facilities. High customer concentration, shareholder dilution and competition from giants like Zoetis and Merck also pose risks.
Yet, robust customer demand for First Defense has been a key driver of sales growth. The remediation of contamination issues and investments in capacity expansion have positioned the company to stabilize output at higher levels.
(You can read the full research report on Immucell here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.